GLP1 receptor agonists are widely prescribed to help control blood sugar levels and support weight loss. While these ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

Drugmaker Abbott India reported a jump in third-quarter profit on Wednesday, helped by strong demand for its gastrointestinal and heart disease medications, sending shares higher.

Obesity is a growing concern worldwide, including in low- and middle-income countries (LMICs). Addressing this issue involves various strategies, including dietary and lifestyle changes, medical ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

The global orally disintegrating tablet market size was valued at USD 14.76 billion in 2024 and is projected to grow from USD 16.33 billion in 2025 to USD 28.88 billion by 2033, exhibiting a CAGR of 7 ...

Irritable bowel syndrome (IBS) is a common digestive disorder with unclear causes, affecting about 10% of the global population. Researchers have now discovered that opioid delta-receptor agonists may ...

A group of 18 colorectal cancer patients experienced complete remission after taking the experimental drug dostarlimab for ...

A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, potentially improving survival and expanding treatment options. A novel approach ...

Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.